文献速递乳腺癌放疗胸部肿瘤放疗

乳腺癌辅助放疗后心脏变化的演变:六年随访研究

The evolution of cardiac changes after breast cancer adjuvant radiotherapy - A six-year follow-up study.
PubMed 文献 · Clin Transl Radiat Oncol · 2025-11-15

结果显示心脏生物标志物显著升高,左侧患者左室收缩功能下降,芳香化酶抑制剂使用和更高平均心脏剂量与更明显心脏损伤相关,提示放疗后亚临床心脏毒性持续存在。

要点

  • 放疗后3年出现亚临床心脏功能减退和生物标志物升高,并持续至6年。
  • 左侧乳腺癌患者左室射血分数、整体纵向应变和每搏输出量显著下降。
  • 芳香化酶抑制剂使用和更高平均心脏剂量与更严重心脏损伤相关。

核心结论

  • 放疗后3年即可见亚临床心脏功能减退和生物标志物升高,并持续至6年,提示永久性心脏效应。
  • 辐射剂量和芳香化酶抑制剂治疗均促成这些心脏变化。

研究设计与样本

  • 量化心脏辐射剂量,并在放疗前及放疗后3年、6年评估超声心动图和血清标志物。

主要发现

  • hscTnT中位数从4 ng/L升至6 ng/L(p<0.001),与左侧患者更高心脏辐射剂量相关。
  • proBNP从78 ng/L升至118 ng/L(p<0.001)。
  • 左侧患者左室射血分数从65%降至60%(p=0.002),整体纵向应变从-18%降至-17%(p=0.006),每搏输出量从74 mL降至67 mL(p=0.015)。
  • 舒张功能障碍亦进展,等容舒张时间和左房射血分数受损。
  • 芳香化酶抑制剂使用和更高平均心脏剂量与更明显心脏损伤相关。

临床怎么用

  • 支持对乳腺癌放疗后患者进行长期心脏监测。
  • 建议使用敏感影像学和生物标志物检测早期放疗诱导的心脏毒性。

局限性

  • 未报告对照组或非放疗比较组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: This prospective study investigated the long-term effects of adjuvant radiotherapy (RT) on cardiac function and biomarkers in early breast cancer patients over a six-year follow-up. METHODS: Seventy-three women treated with RT alone, without chemotherapy, were included. Cardiac radiation doses were quantified, and echocardiography and serum biomarkers (high-sensitivity cardiac troponin T [hscTnT] and N-terminal pro-brain natriuretic peptide [proBNP]) were assessed before RT and at three- and six-years post-treatment. RESULTS: Cardiac biomarkers increased significantly during follow-up. Median hscTnT rose from 4 to 6 ng/L (p<0.001), correlating with higher radiation doses to the heart in left-sided patients. ProBNP increased from 78 to 118 ng/L (p<0.001). Left ventricular (LV) systolic function declined in left-sided patients: ejection fraction decreased from 65% to 60% (p=0.002), global longitudinal strain from -18% to -17% (p=0.006), and stroke volume from 74 to 67 mL (p=0.015). Diastolic dysfunction also progressed, with impairments in isovolumic relaxation time and left atrial ejection fraction. Aromatase inhibitor (AI) use and higher mean heart dose were associated with greater cardiac impairment. CONCLUSION: Subclinical deterioration in cardiac function and elevated biomarkers were evident three years after RT and persisted at six years, suggesting permanent cardiac effects. Both radiation dose and AI therapy contributed to these changes. These findings underscore the importance of long-term cardiac monitoring and support the use of sensitive imaging and biomarkers to detect early radiotherapy-induced cardiotoxicity.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Moisander M, Tuohinen S, Lähdeaho H, et al. The evolution of cardiac changes after breast cancer adjuvant radiotherapy - A six-year follow-up study. Clin Transl Radiat Oncol. 2025. PMID: 41334111. doi:10.1016/j.ctro.2025.101078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。